Osimertinib Plus Chemo Approved for EGFR-mutated NSCLC Osimertinib Plus Chemo Approved for EGFR-mutated NSCLC

With the new approval, patients now have the option of combination treatment or osimertinib monotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news